Madrigal Pharmaceuticals (MDGL) Cash from Operations (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) reported Cash from Operations of 167435000.0 for Q1 2026, down 88.36% year-over-year from 1438432838.99 in Q1 2025, and down 25.46% quarter-over-quarter from 133460000.0 in Q4 2025.
Madrigal Pharmaceuticals (MDGL) Cash from Operations (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has 17 years of Cash from Operations data on file, last reported at 167435000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 167435000.0, down 88.36% year-over-year; the trailing twelve-month figure through Mar 2026 was 268097000.0 (up 32.18% YoY), and the FY2025 annual result was 189553000.0, up 58.39% from the prior year.
- Cash from Operations slipped to 167435000.0 in Q1 2026 per MDGL's latest filing, from 133460000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 79850000.0 in Q3 2025 and troughed at 167435000.0 in Q1 2026.
- A 5-year average of 80096882.35 and a median of 79933000.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2025 and 2026: Cash from Operations jumped 219.21% in 2025, then sank 88.36% in 2026.
- A 5-year view of Cash from Operations shows it stood at 58515000.0 in 2022, then plunged by 36.6% to 79933000.0 in 2023, then plunged by 30.72% to 104486000.0 in 2024, then dropped by 27.73% to 133460000.0 in 2025, then declined by 25.46% to 167435000.0 in 2026.
- Business Quant data shows MDGL's Cash from Operations at 167435000.0 in Q1 2026, 133460000.0 in Q4 2025, and 79850000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Madrigal Pharmaceuticals | 14.67 Bn | 14.44 Bn | - | -167.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -167.44 Mn |
| Mar 31, 2026 | -167.44 Mn |
| Dec 31, 2025 | -133.46 Mn |
| Dec 31, 2025 | -133.46 Mn |
| Sep 30, 2025 | 79.85 Mn |
| Sep 30, 2025 | 79.85 Mn |
| Jun 30, 2025 | -47.05 Mn |
| Jun 30, 2025 | -47.05 Mn |
| Mar 31, 2025 | -88.89 Mn |
| Mar 31, 2025 | -88.89 Mn |
| Dec 31, 2024 | -104.49 Mn |
| Dec 31, 2024 | -104.49 Mn |
| Sep 30, 2024 | -66.98 Mn |
| Sep 30, 2024 | -66.98 Mn |
| Jun 30, 2024 | -134.95 Mn |
| Jun 30, 2024 | -134.95 Mn |
| Mar 31, 2024 | -149.16 Mn |
| Mar 31, 2024 | -149.16 Mn |
| Dec 31, 2023 | -79.93 Mn |
| Dec 31, 2023 | -79.93 Mn |